JP2017007958A - Cream Pharmaceutical Preparation - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide W/O type cream pharmaceutical preparations containing a particular drug, such as crotamiton, the W/O type cream pharmaceutical preparations inhibiting the reduction of formulation viscosity in high- and low-temperature, securing viscosity stability in high- and low-temperature, having a maintainable cream dosage form, and aiming at both moist feel and less stickiness.SOLUTION: A W/O type cream pharmaceutical preparation contains (A) a drug selected from crotamiton, diphenhydramine and a salt thereof, chlorpheniramine and a salt thereof, isothipendyl and a salt thereof, ufenamate, as well as glycyrrhetic acid and a derivative thereof; (B) one or more selected from glycerine fatty acid ester and polyglycerol fatty acid ester, which are an ester compound of a fatty acid having 12 to 22 carbon atoms and (poly)glycerin; (C) a polyoxyethylene hardened castor oil with a polyoxyethylene average addition mole number of 5-20; (D) a silicone oil; and (E) a higher alcohol which is liquid at 25°C.SELECTED DRAWING: None

Description

  The present invention relates to a W / O type cream pharmaceutical preparation containing a specific drug.

  Conventionally, water-in-oil (W / O) creams have been extremely difficult to ensure viscosity stability, and have reduced viscosity after storage under both high temperature conditions (50 ° C) and low temperature conditions (-5 ° C). Technology to suppress has not been established. In particular, when a specific drug such as crotamiton is contained, there is a big problem in the stability of the W / O type cream base. Furthermore, it was difficult for the W / O-type cream base to achieve both the non-stickiness and the feeling of use of the moisturizing feeling.

Japanese Patent Laid-Open No. 2001-151662

  The present invention has been made in view of the above circumstances, and in a W / O type cream pharmaceutical formulation containing a specific drug such as crotamiton, the viscosity of the formulation is suppressed from decreasing at high and low temperatures. The purpose is to ensure the viscosity stability during storage, to maintain the cream form, and to achieve both a non-stickiness and a moisturizing feeling.

  As a result of intensive studies to achieve the above object, the present inventor has (B) a fatty acid having 12 to 22 carbon atoms and (B) a fatty acid having 12 to 22 carbon atoms in a W / O type cream pharmaceutical formulation containing a specific drug such as crotamiton ( (C) polyoxyethylene hydrogenated castor oil having a polyoxyethylene average addition mole number of 5 to 20, selected from glycerin fatty acid ester and polyglycerin fatty acid ester, which is an ester compound of poly) glycerin, (D) By blending silicone oil and (E) a higher alcohol that is liquid at 25 ° C., viscosity stability at low and high temperature storage is ensured, a cream form can be maintained, and there is no stickiness, Has been found that a W / O-type cream pharmaceutical preparation compatible with the above can be obtained, and has led to the present invention.

Accordingly, the present invention provides the following cream pharmaceutical formulation.
[1]. (A) one or more drugs selected from crotamiton, diphenhydramine and salts thereof, chlorpheniramine and salts thereof, isothipentyl and salts thereof, ufenamate, and glycyrrhetinic acid and derivatives thereof (B) a fatty acid having 12 to 22 carbon atoms ( 1 or more types chosen from glycerol fatty acid ester and polyglycerol fatty acid ester which are ester compounds of poly) glycerin (C) polyoxyethylene hydrogenated castor oil (D) silicone oil whose polyoxyethylene average addition mole number is 5-20 And (E) a W / O type cream pharmaceutical preparation containing a higher alcohol that is liquid at 25 ° C.
[2]. The W / O type cream pharmaceutical preparation according to [1], wherein the blending mass ratio of the component (D) and the component (B) represented by (D) / (B) is 0.5 to 3.
[3]. Furthermore, (F) W / O type cream pharmaceutical formulation of [1] or [2] containing a solid wax at 25 ° C.

  According to the present invention, it contains a specific drug such as crotamiton that ensures viscosity stability during storage at low and high temperatures, can maintain a cream formulation, and has both a non-stickiness and a moisturizing feeling. A W / O type cream pharmaceutical preparation can be provided.

Hereinafter, the present invention will be described in detail.
(A) One or more drugs selected from crotamiton, diphenhydramine and its salt, chlorpheniramine and its salt, isothipentyl and its salt, ufenamate, and glycyrrhetinic acid and its derivatives These drugs have anti-inflammatory properties It is an oily active ingredient having a high IOB (0.3 to 0.8). When these ingredients are added, the cream preparation becomes unstable. These can be used individually by 1 type or in combination of 2 or more types. Specifically, crotamiton (0.585), diphenhydramine (0.353), chlorpheniramine (0.500), istipendil (0.722), ufenamate (0.467), glycyrrhetinic acid (0.678) is there. Among them, the effect of the present invention is exhibited more when the cream preparation is destabilized by blending, such as crotamiton, diphenhydramine and its salt, chlorpheniramine and its salt, and ufenamate.

  The blending amount of the component (A) is preferably 0.5 to 15% by mass in the cream pharmaceutical preparation from the viewpoint of effectiveness and the intended effect, and 1.0 to 10% by mass from the viewpoint of high temperature viscosity stability. More preferred.

(B) 1 or more types chosen from glycerol fatty acid ester and polyglycerol fatty acid ester which are ester compounds of a C12-C22 fatty acid and (poly) glycerol As glycerol fatty acid ester, glyceryl monooleate, glyceryl monomyristate Glyceryl monopalmitate, glyceryl monostearate, glyceryl monoisostearate and the like. Examples of the polyglycerin fatty acid ester include polyglycerin fatty acid esters having 2 or more glycerin addition moles, such as polyglyceryl trioleate, polyglyceryl pentaoleate, polyglyceryl pentastearate, polyglyceryl heptaoleate, and polyglyceryl condensed ricinoleate. These can be used individually by 1 type or in combination of 2 or more types.

  Of these, polyglycerin fatty acid esters are preferred from the viewpoint of viscosity stability. Specifically, polyglyceryl fatty acid ester having a glycerin addition mole number of 2 or more, preferably 5 to 10, such as polyglyceryl trioleate, polyglyceryl pentaoleate, polyglyceryl pentastearate, polyglyceryl heptaoleate, or polyglyceryl condensed ricinoleate Is mentioned. From the viewpoint of viscosity stability, the fatty acid is preferably an unsaturated fatty acid. In particular, 12 to 22 carbon atoms, preferably 14 to 18 unsaturated fatty acids having 3 to 10 carbon atoms, preferably 3 to 7 ester bonds, and the number of moles of glycerin added is 2 or more, preferably 5 to 10. Polyglycerin fatty acid esters are preferred. Specific examples include polyglyceryl trioleate, polyglyceryl pentaoleate, and polyglyceryl heptaoleate.

  The HLB of the component (B) is preferably 2 to 7, but the feature of the present invention is that a specific component (B) is used, and as is clear from the results of Examples and Comparative Examples described later, (B The effects of the present invention cannot be obtained even if HLB 2 to 7 other than the component) are used. In the present invention, HLB refers to a value obtained by the Griffin method (see Yoshida, Shindo, Ogaki, Yamanaka, edited by “New Edition Surfactant Handbook”, Engineering Books Co., Ltd., 1991, page 234). ).

  The blending amount of the component (B) in the cream pharmaceutical preparation is preferably 1 to 6% by mass from the viewpoint of the intended effect, and 1.0% from the viewpoint of the balance between high temperature viscosity stability and non-stickiness and moisturizing feeling. -3.5 mass% is more preferable, 1.5-3.5 mass% is further more preferable from the point of high temperature viscosity stability, and 2-3 mass% is especially preferable.

(C) Polyoxyethylene hydrogenated castor oil whose polyoxyethylene average addition mole number is 5-20 As (C) component, it can be used individually by 1 type or in combination of 2 or more types, Polyoxyethylene hydrogenated castor Oil (5E.O.), polyoxyethylene hydrogenated castor oil (7E.O.), polyoxyethylene hydrogenated castor oil (10E.O.), polyoxyethylene hydrogenated castor oil (20E.O.) and the like. . Among these, those having a polyoxyethylene (EO) average added mole number of 7 to 20 are preferable, and those of 10 are more preferable.

  The blending amount of the component (C) in the cream pharmaceutical preparation is preferably 4 to 16% by mass from the viewpoint of the intended effect, more preferably 6 to 14% by mass from the viewpoint of high temperature viscosity stability, and 8 to 12%. More preferred is mass%. Moreover, it becomes easy to extend a formulation by mix | blending (C) component.

(D) Silicone oil Examples of the silicone oil include dimethylpolysiloxane and cyclopentasiloxane, and dimethylpolysiloxane is preferred. These can be used individually by 1 type or in combination of 2 or more types. By blending the component (D), high temperature viscosity stability and no stickiness are improved.

  The blending amount of the component (D) in the cream pharmaceutical preparation is preferably 1 to 10% by mass from the viewpoint of the intended effect, and more preferably 1.5 to 8% by mass from the viewpoint of high temperature viscosity stability. 2-6 mass% is further more preferable. From the point of non-stickiness, 8% by mass or more is preferable.

(E) Higher alcohol that is liquid at 25 ° C. As the component (E), a higher alcohol having 12 to 22 carbon atoms, preferably 14 to 20 liquid that is liquid at 25 ° C., may be used alone or in combination of two or more. They can be used in appropriate combinations. For example, when a higher alcohol that is solid at 25 ° C. is used, even if it is used in combination with a higher alcohol that is liquid at 25 ° C., crystals precipitate and the appearance of the cream pharmaceutical preparation deteriorates. Specific examples of the component (E) include oleyl alcohol, octyl decanol, hexyl decanol and the like, and among them, those which do not contain a branched chain in the structure are preferable. Specific examples include oleyl alcohol.

  The blending amount of the component (E) in the cream pharmaceutical preparation is preferably 0.5 to 5% by mass from the viewpoint of the intended effect, and 1 to 4% by mass from the viewpoint of low temperature viscosity stability and high temperature viscosity stability. Is more preferable.

(F) Solid wax at 25 ° C. The cream pharmaceutical preparation of the present invention preferably contains a solid wax at 25 ° C. from the viewpoint of further improving low temperature viscosity stability, high temperature viscosity stability and moisturizing feeling. Examples of the wax that is solid at 25 ° C. include ester waxes such as beeswax, mole, and candelilla wax, and hydrocarbon waxes such as paraffin wax, ceresin, and microcristane wax, which may be used alone or in combination of two or more. Can be used. Among these, 25 ° C. solid hydrocarbon waxes such as paraffin wax, ceresin, and microkristane wax are preferable, and ceresin is more preferable.

  The blending amount of the component (F) in the cream pharmaceutical preparation is preferably 0.1 to 5% by mass, more preferably 0.5 to 4% by mass, from the viewpoints of low temperature viscosity stability, high temperature viscosity stability and moisturizing feeling. .

  The blending mass ratio of the (D) component and the (B) component represented by (D) / (B) is preferably 0.2 to 5, and low temperature viscosity stability, high temperature viscosity stability, and no stickiness and moisture retention. From the point of balance of feeling, 0.5 to 3 is more preferable, and 0.5 to 2 is more preferable.

  The blending mass ratio of the component (A) and the component (D) represented by (A) / (D) is preferably 0.3 to 8, and more preferably 0.5 to 4 from the viewpoint of high temperature viscosity stability. .

  In the cream pharmaceutical preparation of the present invention, an optional component to be blended in the cream pharmaceutical preparation can be blended in an appropriate amount alone or in combination of two or more, as long as the effects of the present invention are not impaired. As optional components, other chemicals, liquid solvents other than (E) component, humectants, thickeners, chelating agents, preservatives, powder components, solid fats and oils, waxes, solid hydrocarbon oils other than (F) components, Examples thereof include film agents, ultraviolet absorbers, amino acids, organic amines, polymer emulsions, water-soluble polymer compounds, and fragrances.

  The drug is not particularly limited as long as it can be incorporated into an external preparation. For example, prednisolone valerate acetate, tocopherol acetate, allantoin, methyl salicylate, isopropylmethylphenol, lidocaine, l-menthol, panthenol, heparin A similar substance, urea, etc. are mentioned.

  Examples of the solvent that is liquid at 25 ° C. other than the component (E) include squalane, liquid paraffin, and isopropyl myristate. (E) As for the compounding quantity of liquid solvents other than a component, 1-20 mass% is preferable in a cream pharmaceutical formulation.

  Examples of the humectant include chondroitin sulfate, hyaluronic acid, mucoitin sulfate, caronic acid, atelocollagen, cholesteryl-12-hydroxystearate, sodium lactate, bile salt, dl-pyrrolidone carboxylate, short chain soluble collagen, diglycerin. (EO) PO adduct, Izayoi rose extract, Achillea millefolium extract, Merirot extract and the like.

  Examples of the thickener include carboxyvinyl polymer, acrylic acid / alkyl methacrylate copolymer, gum arabic, carrageenan, caraya gum, gum tragacanth, carob gum, quince seed (malmello), casein, dextrin, gelatin, sodium pectate, allagin Sodium acid, methylcellulose, ethylcellulose, CMC (carboxymethylcellulose), hydroxyethylcellulose, hydroxypropylcellulose, PVA (polyvinyl alcohol), PVM (polyvinylmethylether), PVP (polyvinylpyrrolidone), sodium polyacrylate, dimethylacrylamide / acryloyldimethyltaurine Salt-crosslinked polymer, hydroxyethyl acrylate / acryloyldimethyltaurine salt-crosslinked polymer, Locust bean gum, guar gum, Tamarintogamu, dialkyldimethylammonium sulfate cellulose, xanthan gum, aluminum magnesium silicate, bentonite, hectorite, A1Mg silicate (Veegum), laponite, and the like silicic anhydride.

  Examples of the chelating agent include 1-hydroxyethane-1,1-diphosphonic acid, 1-hydroxyethane-1,1-diphosphonic acid tetrasodium salt, disodium edetate, trisodium edetate, tetrasodium edetate, Examples include sodium acid, sodium polyphosphate, sodium metaphosphate, gluconic acid, phosphoric acid, citric acid, ascorbic acid, succinic acid, edetic acid, and trisodium ethylenediaminehydroxyethyl triacetate.

  Examples of the preservative include methyl paraben, ethyl paraben, butyl paraben, phenoxyethanol and the like.

  Examples of the powder component include inorganic powders (for example, talc, kaolin, mica, sericite (sericite), muscovite, phlogopite, synthetic mica, saucite, biotite, vermiculite, magnesium carbonate, calcium carbonate, silicic acid. Aluminum, barium silicate, calcium silicate, magnesium silicate, strontium silicate, metal tungstate, magnesium, silica, zeolite, barium sulfate, calcined calcium sulfate (baked gypsum), calcium phosphate, fluorine apatite, hydroxyapatite, ceramic powder Metal soap (eg, zinc myristate, calcium palmitate, aluminum stearate), boron nitride, etc .; organic powder (eg, polyamide resin powder (nylon powder), polyethylene powder, polymethyl methacrylate powder, Styrene powder, copolymer resin powder of styrene and acrylic acid, benzoguanamine resin powder, polytetrafluoroethylene powder, cellulose powder, etc.); inorganic white pigment (for example, titanium dioxide, zinc oxide, etc.); inorganic red pigment ( For example, iron oxide (Bengara), iron titanate, etc.); inorganic brown pigment (for example, γ-iron oxide, etc.); inorganic yellow pigment (for example, yellow iron oxide, loess, etc.); inorganic black pigment (for example, Black iron oxide, low-order titanium oxide, etc.); inorganic purple pigments (eg, mango violet, cobalt violet, etc.); inorganic green pigments (eg, chromium oxide, chromium hydroxide, cobalt titanate, etc.); inorganic blue pigments (Eg, ultramarine, bitumen, etc.); pearl pigments (eg, titanium oxide coated mica, titanium oxide coated bismuth oxychloride, titanium oxide coated) Talc, colored titanium oxide coated mica, bismuth oxychloride, fish scale foil, etc.); metal powder pigments (eg, aluminum powder, copper powder, etc.); organic pigments such as zirconium, barium or aluminum lake (eg, red 201, red 202) , Red 204, red 205, red 220, red 226, red 228, red 405, orange 203, orange 204, yellow 205, yellow 401, and blue 404 Red No. 3, Red No. 104, Red No. 106, Red No. 227, Red No. 230, Red No. 401, Red No. 505, Orange No. 205, Yellow No. 4, Yellow No. 5, Yellow No. 202, Yellow No. 203, Green No. 3 and Blue No. 1); natural pigments (for example, chlorophyll, β-carotene, etc.) and the like.

  Examples of the solid fat include cacao butter, palm oil, horse fat, hydrogenated palm oil, palm oil, beef tallow, sheep fat, hydrogenated beef tallow, palm kernel oil, pork fat, beef bone fat, owl kernel oil, hydrogenated oil, cattle Leg fats, moles, hydrogenated castor oil and the like.

  Examples of the wax include beeswax, candelilla wax, cotton wax, carnauba wax, bayberry wax, ibota wax, whale wax, montan wax, nuka wax, lanolin, kapok wax, lanolin acetate, liquid lanolin, sugar cane wax, lanolin fatty acid isopropyl, hexyl laurate, reduced lanolin, Examples include jojoba wax, hard lanolin, shellac wax, POE lanolin alcohol ether, POE lanolin alcohol acetate, POE cholesterol ether, lanolin fatty acid polyethylene glycol, and POE hydrogenated lanolin alcohol ether.

  Examples of the solid hydrocarbon oil other than the component (F) include petrolatum, gelled hydrocarbon, and the like.

  Examples of the ultraviolet absorber include benzoic acid-based ultraviolet absorbers (for example, paraaminobenzoic acid (hereinafter abbreviated as PABA), PABA monoglycerin ester, N, N-dipropoxy PABA ethyl ester, N, N-diethoxy PABA ethyl ester. N, N-dimethyl PABA ethyl ester, N, N-dimethyl PABA butyl ester, N, N-dimethyl PABA ethyl ester, etc.); anthranilic acid ultraviolet absorbers (for example, homomenthyl-N-acetylanthranylate, etc.); Salicylic acid UV absorbers (eg, amyl salicylate, menthyl salicylate, homomenthyl salicylate, octyl salicylate, phenyl salicylate, benzyl salicylate, p-isopropanol phenyl salicylate); (For example, octylmethoxycinnamate, ethyl-4-isopropylcinnamate, methyl-2,5-diisopropylcinnamate, ethyl-2,4-diisopropylcinnamate, methyl-2,4-diisopropylcinnamate, propyl-p- Methoxycinnamate, isopropyl-p-methoxycinnamate, isoamyl-p-methoxycinnamate, octyl-p-methoxycinnamate (2-ethylhexyl-p-methoxycinnamate), 2-ethoxyethyl-p-methoxycinnamate, Cyclohexyl-p-methoxycinnamate, ethyl-α-cyano-β-phenylcinnamate, 2-ethylhexyl-α-cyano-β-phenylcinnamate, glyceryl mono-2-ethylhexanoyl-diparamethoxycinnamate, etc. ); 3- (4′-methylbenzylidene) -d, l-camphor, 3-benzylidene-d, l-camphor; 2-phenyl-5-methylbenzoxazole; 2,2′-hydroxy-5-methylphenyl 2- (2'-hydroxy-5'-t-octylphenyl) benzotriazole; 2- (2'-hydroxy-5'-methylphenyl) benzotriazole; dibenzalazine; dianisoylmethane; 4-methoxy-4 '-T-butyldibenzoylmethane; 5- (3,3-dimethyl-2-norbornylidene) -3-pentan-2-one, dimorpholinopyridazinone and the like.

  Examples of amino acids include neutral amino acids (eg, threonine, cysteine, etc.); basic amino acids (eg, hydroxylysine, etc.) and the like. Examples of the amino acid derivative include acyl sarcosine sodium (lauroyl sarcosine sodium), acyl glutamate, acyl β-alanine sodium, glutathione, and pyrrolidone carboxylic acid.

  Examples of the organic amine include monoethanolamine, diethanolamine, triethanolamine, morpholine, triisopropanolamine, 2-amino-2-methyl-1,3-propanediol, 2-amino-2-methyl-1-propanol, and the like. Is mentioned.

  Examples of the polymer emulsion include an acrylic resin emulsion, a polyethyl acrylate emulsion, an acrylic resin liquid, a polyacryl alkyl ester emulsion, a polyvinyl acetate resin emulsion, and a natural rubber latex.

  The cream pharmaceutical preparation of the present invention has, for example, (A) to (E), and if necessary, an oil phase containing components (A) to (F) heated to 60 to 80 ° C and dissolved in an oil phase of 60 to An aqueous phase heated to 80 ° C. is added, emulsified using a homomixer or the like, and then cooled to room temperature.

  The cream pharmaceutical preparation of the present invention is a W / O type cream pharmaceutical preparation. The emulsification type is roughly classified into a W / O type and an O / W type. When an active ingredient such as the above (A) is blended, the W / O type is superior in the retention effect on the skin as compared to the O / W type, and the effect of the active ingredient can be exhibited more.

  The viscosity that can be said to be a cream is 10 to 100 Pa · s at 25 ° C., preferably 20 to 70 Pa · s, and more preferably 25 to 50 Pa · s. When the viscosity is below the range of the cream, it cannot be applied effectively to the affected area, and drainage from a container such as a tube decreases due to dripping. On the other hand, if the viscosity is too high, the easiness of stretching may be reduced. The viscosity is measured under the conditions of a B-type viscometer (25 ° C., 20 rpm, rotor No. 6).

  3-6 are preferable at 25 degreeC, and, as for pH (25 degreeC) of the cream pharmaceutical formulation of this invention, 4-6 are more preferable. Cream pharmaceutical preparations are preferably weakly acidic to the skin. As the pH adjuster, monovalent organic acids such as lactic acid or salts thereof, polyvalent organic acids such as citric acid, succinic acid, malic acid and / or salts thereof, boric acid or borax are preferable. The pH adjuster can be used singly or in appropriate combination of two or more, and the amount of the pH adjuster is appropriately selected as the pH of the cream pharmaceutical preparation.

  EXAMPLES Hereinafter, although an Example and a comparative example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to the following Example. In the following examples, unless otherwise specified, “%” in the composition represents mass%, and the ratio represents mass ratio.

[Examples 1 to 51, Comparative Examples 1 to 6]
The water phase heated to 70 ° C. is added to the oil phase (components (A) to (E) and squalane and the like (components (A) to (F) as necessary) dissolved at 70 ° C. The mixture was emulsified at 6,000 rpm (70 ° C.) using a mixer (TK AUTO HOMO MIXER manufactured by Tokushu Kika Kogyo Co., Ltd.). Then, it cooled to room temperature and deaerated. The following measurements and evaluations were performed on the obtained emulsion. The results are also shown in the table. In addition, as a result of determining an emulsion type by electrical conductivity, the emulsion obtained in the Example and the comparative example was a W / O type emulsion. It was 4.5-7.0 when the pH (25 degreeC) of the emulsion was measured using the following apparatus.
・ PH meter: F-71S type manufactured by HORIBA, Ltd. ・ pH electrode: 6377-10D type manufactured by HORIBA, Ltd.

<Cream type>
Measured under the following conditions using a B-type viscometer (Tokyo Keiki ASB100 type), 10 to 100 Pa · s is indicated as “cream type”, and is indicated by “◯” in the table, and less than 10 Pa · s. Or what was not suitable as a "cream dosage form" exceeding 100 Pa.s was shown by "x" in the table | surface. Immediately after the production and after low temperature: −5 ° C. and high temperature: 50 ° C. were evaluated after storage for 2 months.
Rotor: No. 6
Measurement temperature: 25 ° C
20 rpm

<Viscosity retention and viscosity stability>
The emulsion is stored at low temperature: −5 ° C. and high temperature: 50 ° C. for 2 months, respectively. The viscosity immediately after production and the viscosity after storage for 2 months are measured using a B-type viscometer (Tokyo Keiki ASB100). The measurement was performed under the following conditions.
Rotor: No. 6
Measurement temperature: 25 ° C
20 rpm
From the measurement results, the viscosity retention rate (%) is calculated using the following formula, and the viscosity retention rate is shown based on the following evaluation criteria.
Viscosity retention (%) = viscosity after storage for 2 months / viscosity immediately after production × 100
(Viscosity stability evaluation criteria)
7: 95% or more 6: 90% or more but less than 95% 5: 80% or more but less than 90% 4: 70% or more but less than 80% 3: 60% or more but less than 70% 2: 50% or more but less than 60% 1: less than 50% Measurement not possible (oil-water separation)
Accept 3 or more points

<No stickiness>
Ten panelists spread about 0.5 g of the emulsion on the forearms of the panelists and performed sensory evaluation on the absence of stickiness after 5 minutes based on the following scores. A result is shown with the following evaluation criteria based on the average score of 10 persons.
(Score)
6 points: I don't feel 5 points: I don't feel much 4 points: Slightly feel 3 points: I feel a little 2 points: I feel very much 1 point: I feel very much (Evaluation criteria for no stickiness)
6: Average point 5.5 or more 5: Average point 5.0 or more and less than 5.5 4: Average point 4.0 or more and less than 5.0 3: Average point 3.0 or more and less than 4.0 2: Average point 2 0 or more and less than 3.0 1: Average point less than 2.0 and 3 or more points as pass

<Moisturizing feeling>
Ten panelists spread about 0.5 g of the emulsion on the forearm of the panel and performed a sensory evaluation on the moisturizing feeling after 3 hours based on the following scores. A result is shown with the following evaluation criteria based on the average score of 10 persons.
(Score)
6 points: very felt 5 points: very felt 4 points: felt 3 points: a little felt 2 points: not much felt 1 point: not felt (moisturizing evaluation criteria)
6: Average point 5.5 or more 5: Average point 5.0 or more and less than 5.5 4: Average point 4.0 or more and less than 5.0 3: Average point 3.0 or more and less than 4.0 2: Average point 2 0 or more and less than 3.0 1: Average point less than 2.0 and 3 or more points as pass

The raw materials used in preparing the examples and comparative examples are shown below. Unless otherwise specified, the amount of each component in the table is a pure conversion amount.
・ Ufenamate: Shiono Finesse Ufenamato crotamiton: Sumitomo Chemical Co., Ltd. Crotamiton diphenhydramine: Kongo Chemical JP Diphenhydramine, diphenhydramine hydrochloride: Kongo Chemical Co., Ltd. Co., Ltd. Prednisolone valerate / Glycyrrhetinic acid: Maruzen Pharmaceutical Co., Ltd. Glycyrrhetinic acid / Allantoin: Permachem Asia Co., Ltd. Allanto Chlorpheniramine Artis Chemistry (Shanghai) Co., Ltd. Ltd ..
・ Pentaoleic acid decaglyceryl (HLB3.5): Nihon Surfactant Industrial Co., Ltd. NIKKOL Decaglyn 5-OV
-Decaglyceryl heptaoleate (HLB3.0): Nihon Surfactant Industrial Co., Ltd. NIKKOL Decaglyn 7-OV
・ Glyceryl monooleate (HLB2.5): Nikko Chemicals Corporation NIKKOL MGO
・ Sorbitan monooleate (HLB4.3): Nikko Chemicals Corporation NIKKOL SO-10V
Condensed ricinoleate hexaglyceryl (HLB3.5): Nikko Chemicals Corporation NIKKOL Hexaglyn PR-15
Polyoxyethylene hydrogenated castor oil (20E.O.) (HLB10.5): Nikko Chemicals Co., Ltd. NIKKOL HCO-20
Polyoxyethylene hydrogenated castor oil (10E.O.) (HLB6.5): Nikko Chemicals Corporation NIKKOL HCO-10
Polyoxyethylene hydrogenated castor oil (5E.O.) (HLB 6.0): Nikko Chemicals Corporation NIKKOL HCO-5
Polyoxyethylene hydrogenated castor oil (60E.O.) (HLB14.0): Nikko Chemicals Corporation NIKKOL HCO-60
・ Dimethylpolysiloxane: Shin-Etsu Chemical Co., Ltd. KF-96A-10CS
Cyclopentasiloxane: Toray Dow Corning Co., Ltd. ST-Cyclomethicone 5-NF
・ Squalane: Nikko Chemicals Co., Ltd. NIKKOL Squalane Macrogol 20000: Sanyo Chemical Co., Ltd. Macrogol 20000, average molecular weight 20,000
-Ceresin: Purified ceresin N, Nikko Rica Co., Ltd.
・ Paraffin wax: Nikko Rica Co., Ltd. Refined paraffin wax ・ Micro Kristan wax: Nikko Rica Co., Ltd. Purified micro-Crystan wax ・ Oleyl alcohol: Croda Japan Co., Ltd. Novol-LQ- (JP)
・ Octyldodecanol: Kao Co., Ltd. Calcoal 200GD
-Hexyldecanol: Kao Corporation Risonol 16SP
・ Glycerin: Sakamoto Pharmaceutical Co., Ltd. Japanese Pharmacopoeia Glycerin ・ DL-malic acid: Fuso Chemical Co., Ltd. DL-malic acid

Claims (3)

(A) one or more drugs selected from crotamiton, diphenhydramine and salts thereof, chlorpheniramine and salts thereof, isothipentyl and salts thereof, ufenamate, and glycyrrhetinic acid and derivatives thereof (B) a fatty acid having 12 to 22 carbon atoms ( 1 or more types chosen from glycerol fatty acid ester and polyglycerol fatty acid ester which are ester compounds of poly) glycerin (C) polyoxyethylene hydrogenated castor oil (D) silicone oil whose polyoxyethylene average addition mole number is 5-20 And (E) a W / O type cream pharmaceutical preparation containing a higher alcohol that is liquid at 25 ° C.   The W / O type cream pharmaceutical preparation according to claim 1, wherein the blending mass ratio of the component (D) and the component (B) represented by (D) / (B) is 0.5-3.   Furthermore, (F) W / O type cream pharmaceutical formulation of Claim 1 or 2 containing a solid wax at 25 degreeC.